Articles tagged with Tyrosine Kinase Inhibitors
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Researchers identified fexofenadine as a potential Met-inhibitor that can overcome osimertinib resistance in NSCLC. The study found that fexofenadine enhances the anticancer effect of osimertinib in both laboratory and mouse models, making it a promising repurposed drug for treating NSCLC.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
A new study introduces a multi-omics-based molecular classification of gastrointestinal stromal tumors, categorizing them into four distinct subtypes. The findings identify key genetic signatures and tumor suppressor genes that influence treatment response, providing a roadmap for personalized therapy strategies.
Researchers tested tivozanib with nivolumab in patients with advanced clear cell renal cell carcinoma and found no benefit from combining the two treatments. Repeat ICI therapy should be discouraged due to lack of improvement in overall survival or response rates.
A team of researchers from Penn State College of Medicine identified KDR, a tyrosine kinase, as a potential drug target for treating diseases caused by human T-cell leukemia virus type 1 (HTLV-1). By blocking KDR, the viral protein Tax is degraded, leading to cell death and disruption of cancer-causing signaling pathways.
A team of Penn State researchers has created a modular genetic circuit that turns cancer cells into a 'Trojan horse,' causing them to self-destruct and kill nearby drug-resistant cancer cells. The circuit outsmarts resistance and eliminates it before the cancer cells can evolve.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
Ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared to chemotherapy alone in TKI-treated non-small cell lung cancer patients. This treatment may offer a new option for patients with EGFR variant and limited treatment options.
Researchers identified NTRK gene fusion in 1.5% of Finnish papillary thyroid cancer patients, with notable co-occurring genetic alterations and favorable treatment outcomes. The study highlights the potential for biobank samples linked to electronic health records to describe patient characteristics and outcomes.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers describe the use of ripretinib and repeated surgical resection in a patient with recurrent GIST harboring a KIT exon 11 mutation. The treatment led to extended clinical benefit, outperforming current reported data from ripretinib clinical trials.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.
In a multicenter trial, pirtobrutinib demonstrated reversible and effective inhibition of defective B-cells in patients with poor survival prognosis. Over half of patients responded to the drug, with a median duration of response of 21.6 months.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
A phase 2 clinical trial has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus. The study found that patients treated with deucravacitinib experienced significant improvements in disease activity, with response rates ranging from 34% to 58% compared to placebo.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
A study published in Nature Communications reveals the mechanisms of SARS-CoV-2 proteolysis and identifies key cellular substrates with therapeutic potential. The research provides a powerful resource for developing targeted strategies to inhibit the virus, which has caused over 227 million infections and 4.6 million deaths worldwide.
A study identifies four novel subgroups of EGFR mutations that predict drug response, offering a more accurate framework to match patients with targeted therapies. The findings reveal that certain mutations respond better to specific classes of TKIs, providing new clinical opportunities for approved treatments.
Researchers at Kanazawa University have found that combining alectinib with ixazomib, a proteasome inhibitor, restores the efficacy of alectinib in patients with NSCLC who develop secondary TP53 mutations. This combination therapy has shown promising results in preclinical trials.
A new deep learning model using PET/CT imaging can classify EGFR mutation status in non-small cell lung cancer, predicting the most effective treatment option. The model shows promise as a clinical decision support tool for personalized treatment choices.
A new potential drug treatment has been discovered for a type of lung-cancer. Researchers have found that combining osimertinib with linsitinib can cure or delay tumor recurrence in EGFR-mutated lung cancer, even in AXL-low expressing tumors.
Research reveals SIRT1's crucial role in maintaining regenerative potential of CML leukemic stem cells and promoting leukemia development. The study suggests targeting persistent leukemic stem cells with kinase-independent metabolic alterations.
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers at St. Jude Children's Research Hospital discovered that combining tyrosine kinase inhibitors with an FAK inhibitor synergizes to decrease tumor growth in mouse models of BCR-ABL1+ B-progenitor ALL. This combination approach is a promising treatment strategy for this subset of ALL.
A recent study published in Journal of Thoracic Oncology found that the FDA-approved VENTANA anti-ALK(D5F3)CDx assay is superior to the 5A4 IHC assay for selecting patients with non-small cell lung cancer eligible for ALK tyrosine kinase inhibitor treatment.
The American Thoracic Society has released updated guidelines for the treatment of idiopathic pulmonary fibrosis (IPF), emphasizing a patient-centered approach. The new guidelines recommend against certain treatments, including anticoagulation and imatinib, while encouraging the use of nintedanib and pirfenidone.
The IMPRESS trial found that continued gefitinib therapy after resistance development in lung cancer did not improve progression-free survival. Chemotherapy alone remains the standard treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Researchers at Moffitt Cancer Center found that chronic myeloid leukemia patients taking tyrosine kinase inhibitors experience distressing side effects such as depression, fatigue, nausea, and changes in appearance. These issues can significantly impact patients' quality of life for the rest of their treatment period.
Researchers identified a potential combination therapy to effectively use receptor tyrosine kinases inhibitors for KRAS mutant colorectal cancers by combining with MEK/ERK signaling pathway inhibitors. This approach could offer new treatment options for individuals with KRAS mutant cancers.
A new treatment approach targeting CML stem cells is being tested, offering a potential cure for patients resistant to Tyrosine Kinase Inhibitors. Hydroxychloroquine has shown promise in killing cancer cells undergoing autophagy, a state that allows them to survive and return after standard therapy.
The European Association of Urology Congress highlights advances in renal cell carcinoma management, including immunotherapy, targeted therapies, and angiogenesis blockers. New treatments like bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus have shown promise in stabilizing metastatic kidney cancer for a certain period.
Masitinib targets mast cells and shows greater activity and selectivity against KIT than benchmark TKI imatinib. The study demonstrates masitinib's potential in treating KIT and PDGFR-dependent diseases, including various cancers, inflammatory diseases, and neurological indications.
A new online database provides a comprehensive list of somatic EGFR mutations, allowing clinicians to make more robust decisions about treatment options for non-small-cell lung cancer patients. The database includes data from thousands of patients and offers improved treatment outcomes for those receiving tyrosine kinase inhibitors.
Aptamers may have therapeutic effects against cancer by blocking RET downstream signaling events. The study uses whole-cell SELEX to identify macromolecules with potential therapeutic effects against other transmembrane receptors involved in tumorigenesis.